Global Chronic Pruritus Therapeutics Market Size To Surpass USD 12.1 Billion By 2030 | CAGR of 4.4%
17 avr. 2023 06h10 HE
|
SPHERICAL INSIGHTS LLP
New York, United States , April 17, 2023 (GLOBE NEWSWIRE) -- The Global Chronic Pruritus Therapeutics Market Size is To Grow from USD 8.2 Billion in 2021 to USD 12.1 Billion by 2030, at a Compound...
Trevi Therapeutics Announces Positive Outcome of the Sample Size Re-Estimation Analysis in PRISM Trial for Severe Pruritus in Patients With Prurigo Nodularis
13 juil. 2020 07h30 HE
|
Trevi Therapeutics
Independent Data Monitoring Committee Recommends Continuation of PRISM Trial with Expansion to 360 Subjects per the Adaptive Design Enrollment Expected to be Complete by Third Quarter 2021 ...
Trevi Therapeutics Announces First Quarter 2020 Financial Results and Corporate Update
07 mai 2020 16h05 HE
|
Trevi Therapeutics
Sample Size Re-Estimation Analysis for PRISM Trial Expected in Mid-2020 New Patient Screening Re-Starting at PRISM Sites in the US and Europe Cash Position of $52.6 Million Expected to Fund...
Trevi Therapeutics Announces Third Quarter 2019 Financial Results and Recent Business Developments
14 nov. 2019 16h05 HE
|
Trevi Therapeutics
Advancement of Nalbuphine ER in Clinical Development for Three Indications Cash Position of $63.5 Million Expected to Fund Operations Through At Least Q1 2021 NEW HAVEN, Conn., Nov. 14, 2019 ...
Trevi Therapeutics to Present at Stifel Healthcare Conference
13 nov. 2019 17h01 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics to Participate in Panel Discussion at BTIG Pain / Pruritus Management Forum
05 sept. 2019 16h05 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
Trevi Therapeutics Announces Second Quarter 2019 Financial Results and Recent Business Developments
12 août 2019 16h05 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
18 juin 2019 16h05 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., June 18, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics Announces First Quarter 2019 Financial Results and Recent Business Developments
13 juin 2019 16h09 HE
|
Trevi Therapeutics
Raised $70 Million in Gross Proceeds from Initial Public Offering and Concurrent Private Placement Initiated Phase 2 Clinical Trial for Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis...
Trevi Therapeutics Announces Pricing of Initial Public Offering
07 mai 2019 13h22 HE
|
Trevi Therapeutics
NEW HAVEN, Conn., May 07, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to...